The potential of FimH as a novel therapeutic ...
Type de document :
Article dans une revue scientifique
PMID :
URL permanente :
Titre :
The potential of FimH as a novel therapeutic target for the treatment of Crohn's disease
Auteur(s) :
Sivignon, Adeline [Auteur]
Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte [M2iSH]
Bouckaert, Julie [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle UMR 8576 [UGSF]
Bernard, Julien [Auteur]
Ingénierie des Matériaux Polymères [IMP]
Gouin, Sébastien G. [Auteur]
Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation [CEISAM]
Barnich, Nicolas [Auteur]
Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte [M2iSH]
Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte [M2iSH]
Bouckaert, Julie [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle UMR 8576 [UGSF]
Bernard, Julien [Auteur]
Ingénierie des Matériaux Polymères [IMP]
Gouin, Sébastien G. [Auteur]
Chimie Et Interdisciplinarité : Synthèse, Analyse, Modélisation [CEISAM]
Barnich, Nicolas [Auteur]
Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte [M2iSH]
Titre de la revue :
Expert Opinion on Therapeutic Targets
Nom court de la revue :
Expert Opin. Ther. Targets
Numéro :
21
Pagination :
837-847
Date de publication :
2017-08-11
ISSN :
1744-7631
Mot(s)-clé(s) en anglais :
Fimbriae Proteins
Mannosides
Escherichia coli Infection
Adhesins, Escherichia coli
Humans
Escherichia coli
FimH antagonists
Crohn Disease
Inflammation
Molecular Targeted Therapy
Animals
Drug Design
microbiota-targeting therapy
personalized therapy
Mannosides
Escherichia coli Infection
Adhesins, Escherichia coli
Humans
Escherichia coli
FimH antagonists
Crohn Disease
Inflammation
Molecular Targeted Therapy
Animals
Drug Design
microbiota-targeting therapy
personalized therapy
Discipline(s) HAL :
Chimie/Chimie théorique et/ou physique
Résumé en anglais : [en]
INTRODUCTION: Crohn's disease (CD) is a life-long chronic disorder characterized by intestinal inflammation. Current treatments for CD are directed towards abnormal immune responses rather than the intestinal bacteria that ...
Lire la suite >INTRODUCTION: Crohn's disease (CD) is a life-long chronic disorder characterized by intestinal inflammation. Current treatments for CD are directed towards abnormal immune responses rather than the intestinal bacteria that trigger intestinal inflammation. Areas covered: Adherent-Invasive Escherichia coli (AIEC) bacteria abnormally colonize the ileal mucosa in a subgroup of CD patients. They can promote or perpetuate chronic inflammation and are therefore an interesting therapeutic target. Various strategies that target these E. coli strains have been developed to promote their intestinal clearance. Here, we review current AIEC-targeted strategies, especially anti-adhesive strategies, that are based on the development of FimH antagonists. We discuss their potential as personalized microbiota-targeted treatments for CD patients abnormally colonized by AIEC. Expert opinion: A large panel of mannose-derived FimH antagonists were tested for their ability to inhibit E. coli adhesion to host cells. Documented reports suggest that monovalent mannosides are promising candidates that could represent a complementary therapeutic strategy to prevent intestinal inflammation in the E. coli-colonized CD patient subgroup. Ongoing research continues to improve the pharmacokinetic properties of mannosides, and hopefully, clinical trials will be performed in CD patients in the near future.Lire moins >
Lire la suite >INTRODUCTION: Crohn's disease (CD) is a life-long chronic disorder characterized by intestinal inflammation. Current treatments for CD are directed towards abnormal immune responses rather than the intestinal bacteria that trigger intestinal inflammation. Areas covered: Adherent-Invasive Escherichia coli (AIEC) bacteria abnormally colonize the ileal mucosa in a subgroup of CD patients. They can promote or perpetuate chronic inflammation and are therefore an interesting therapeutic target. Various strategies that target these E. coli strains have been developed to promote their intestinal clearance. Here, we review current AIEC-targeted strategies, especially anti-adhesive strategies, that are based on the development of FimH antagonists. We discuss their potential as personalized microbiota-targeted treatments for CD patients abnormally colonized by AIEC. Expert opinion: A large panel of mannose-derived FimH antagonists were tested for their ability to inhibit E. coli adhesion to host cells. Documented reports suggest that monovalent mannosides are promising candidates that could represent a complementary therapeutic strategy to prevent intestinal inflammation in the E. coli-colonized CD patient subgroup. Ongoing research continues to improve the pharmacokinetic properties of mannosides, and hopefully, clinical trials will be performed in CD patients in the near future.Lire moins >
Langue :
Anglais
Audience :
Non spécifiée
Établissement(s) :
CNRS
Université de Lille
Université de Lille
Équipe(s) de recherche :
Computational Molecular Systems Biology
Date de dépôt :
2020-02-12T15:11:25Z
2021-04-21T07:39:42Z
2021-04-21T07:39:42Z